Lynn Gaston
Optometrist · Kansas City, MONPI 1396813473
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Sight Sciences, Inc. at 29.7% of the total. Among optometrist clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 105 payments — averaging $80.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$3K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- Bausch & Lomb Americas Inc.$988
- AbbVie$692
- Sun Pharmaceutical Industries Inc.$503
- Tarsus Pharmaceuticals, Inc.$502
- plus $1K from 10 others
Across 16 payments — averaging $294.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sight Sciences, Inc.$3K
- AbbVie$2K
What the payments were for
- Speaking & faculty fees$2,25027%
- Travel & lodging$2,12225%
- Food & beverage$4,09748%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 5 | $2,518 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $2,144 |
| Bausch & Lomb Americas Inc. | 16 | $988 |
| AbbVie | 32 | $692 |
| Sun Pharmaceutical Industries Inc. | 10 | $503 |
| Tarsus Pharmaceuticals, Inc. | 8 | $502 |
| Alcon | 4 | $314 |
| Glaukos Corporation | 3 | $238 |
| Biotissue Holdings Inc. | 4 | $199 |
| Harrow Eye, LLC | 2 | $139 |
| Mallinckrodt Hospital Products Inc. | 3 | $78 |
| Thea Pharma Inc. | 2 | $49 |
| ANI Pharmaceuticals, Inc. | 2 | $48 |
| Dompe US, Inc. | 1 | $23 |
| Oyster Point Pharma, Inc. | 1 | $23 |
| Johnson & Johnson Vision Care, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEARCARE SYSTEM$2,470
- BIOTRUE$1,716
- ULTRA$1,716
- CEQUA$370
- INFUSE$364
- ULTRA MULTIFOCAL TORIC$243
- XDEMVY$240
- iStent Infinite$181
- iDoseTR$181
- Hydrus Microstent$150
- Rocklatan$133
- Rhopressa$133
- MIEBO$124
- DURYSTA$124
- XEN GLAUCOMA TREATMENT SYSTEM$123
- VYZULTA$119
- BIOTRUE ONE DAY$119
- VEVYE$118
How this compares
$8,469 in reported general payments places this provider in the 95th percentile of 1,030 optometrist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 50 | $46,037 |
| LumiganBimatoprost | 71 | $28,218 |
| Cyclosporine | 37 | $22,064 |
| CombiganBrimonidine Tartrate/Timolol | 24 | $7,387 |
| Travoprost | 22 | $3,419 |
| Prednisolone Acetate | 60 | $2,051 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 52 | $2,032 |
| Latanoprost | 146 | $1,883 |
| Ketorolac Tromethamine | 29 | $661 |
| Brimonidine Tartrate | 12 | $459 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 18 | $358 |
| Ciprofloxacin Hcl | 23 | $238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $692 | $81,642145 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,030 optometrist providers in Missouri.
Other optometrist in Kansas City
- Geoffrey PowellKansas City$55K
- Michael MooreKansas City$18K
- Kristen YatesKansas City$12K
- Crystal RemingtonKansas City$10K
- Kelsey KleinsasserKansas City$10K
- Kelli SmithKansas City$7K
- Andrew BiondoKirkwood$300K
- John McGrealSaint Louis$126K
- Alana KellerWildwood$94K
- Sarah HubbardChesterfield$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.